Drugs / ATX-295
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06799065 | Mar 2025 → Apr 2027 expected | female breast carcinoma, ovarian carcinoma, triple-negative breast carcinoma | Accent Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Accent Therapeutics | Results Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting accenttx.com ↗
Data demonstrate robust and durable anti-cancer activity of ATX-295, a potentially best-in-class KIF18A inhibitor, in multiple preclinical chromosomally instable cancer models |
| 2025-10-22 | Accent Therapeutics | Results Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics accenttx.com ↗
Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced new preclinical data on its two lead programs: the novel KIF18A inhibitor, ATX-295, and the first-in-class DHX9 inhibitor, ATX-559. |
| 2025-04-28 | Accent Therapeutics | Results Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025 accenttx.com ↗
Oral presentation showcases robust, selective activity of potentially best-in-class KIF18A inhibitor, ATX-295, in KIF18A-dependent ovarian cancer models exhibiting whole genome doubling |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATX-295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799065 ↗ |
| Action | Inhibit | “ATX-295 is an oral drug that inhibits a protein called KIF18A” NCT06799065 ↗ |
| Route | Oral | “ATX-295 Tablets will be taken orally” NCT06799065 ↗ |
| Target | KIF18A | “ATX-295 is an oral drug that inhibits a protein called KIF18A” NCT06799065 ↗ |